Skip to main content
Funded Studies

Study in French Population to Identify Therapies with Repurposing Potential for Parkinson’s Disease

Study Rationale:
There is an urgent need to identify effective, safe and inexpensive drugs for Parkinson’s disease, and over past years, there has been increasing interest on ways to repurpose existing medications. A few previous epidemiologic studies showed a decreased risk of Parkinson’s in users of, for example, statins, calcium channel blockers, non-aspirin NSAIDs, ibuprofen and beta2-agonists. If confirmed, these findings may open new avenues for treatment. More pharmacological connections could point to new therapeutic routes.

Our objective is to identify drugs that are associated with a decreased risk of Parkinson’s in two large population-based epidemiological studies to trigger new paths to drug development.

Study Design:
We propose to implement a pharmacoepidemiological study using two complementary approaches: (i) agnostic approach: in a study (~48,000 Parkinson’s cases, 144,000 matched control volunteers) within a French medico-administrative database, we will use sophisticated statistical methods to screen whether people with Parkinson’s have been less often exposed to any type of drug than controls; significant signals will be replicated in an independent cohort; (ii) a priori candidate approach: in both datasets, we will examine association between drugs previously associated with reduced Parkinson’s risk (i.e., non-aspirin NSAIDs and ibuprofen, calcium channel blockers, statins, beta2-agonists).

Impact on Diagnosis/Treatment of Parkinson’s Disease:
The identification of drugs that are associated with decreased Parkinson’s risk may open new paths to develop new treatments in a considerably shorter time and at less cost than traditional approaches to develop drugs.

Next Steps for Development:
The next steps would involve: (i) confirmation of findings in other large-scale databases or cohort studies; (ii) elucidating the mechanisms underlying the inverse association of Parkinson’s with the drug(s) identified in our study as potential candidates; (iii) developing clinical trials to translate findings from our observational study to people with Parkinson’s disease.


Discover More Grants

Search by Related Keywords

Within the Same Funding Year

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.